Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted systems use four targeting orders. First-order systems passively direct drugs to capillary beds of organs or tissues. Second-order systems target specific cells like tumor cells. Third-order systems enable intracellular drug delivery, while fourth-order systems target macromolecules. This hierarchical approach allows precise control over drug localization and therapeutic efficacy.

Passive targeting relies on the carrier system's physicochemical properties, such as size and charge, to enhance drug accumulation at target sites. Active targeting employs ligands or monoclonal antibodies to improve drug specificity and ensure selective uptake. Active targeting reduces off-target effects and enhances therapeutic precision compared to passive approaches.

Drug carriers protect drugs from degradation, improve cellular uptake, and reduce premature clearance through covalent or non-covalent bonding. Polymeric carriers typically comprise a backbone, targeting ligand, solubilizer, and spacer that covalently links the drug. These components work together to facilitate controlled drug release and enhance therapeutic efficacy at target sites.

Liposomes improve drug efficacy and reduce side effects by enhancing drug solubility and stability while minimizing systemic toxicity. Albumin-based carriers prolong drug action by reducing renal clearance, extending circulation time. Both carrier types protect drugs and improve uptake, making them valuable for minimizing treatment costs and adverse effects.

Site-targeted drug delivery systems enhance therapeutic efficacy while reducing side effects and treatment costs associated with conventional approaches. These systems ensure precise drug delivery, improving bioavailability and minimizing systemic toxicity. By directing drugs specifically to diseased tissues or cells, they maximize therapeutic benefit while decreasing off-target exposure.

Lipoproteins facilitate intracellular drug transport through receptor-mediated endocytosis, enabling drugs to reach intracellular targets. Immunoliposomes incorporate monoclonal antibodies in liposomal bilayers, enabling precise targeting of diseased cells. Both approaches combine carrier protection with active targeting mechanisms to enhance specificity and reduce systemic exposure.

The enhanced permeability and retention (EPR) effect is a passive targeting mechanism where carrier systems accumulate at specific sites due to their physicochemical properties, including size and charge. This effect exploits differences in vascular permeability between normal and diseased tissues, allowing drugs to preferentially accumulate in target areas while reducing systemic distribution.